$DAVA

Druskin Ben sold $705 of DAVA

Druskin Ben sold 244 shares of Endava plc (DAVA) at $2.89 on 2026-06-30.

Original reporting
SEC EDGAR · Druskin Ben
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DAVA
Neutral
high confidence
Mentioned
$DAVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DAVANeutralLow
01

Why it matters

The disclosure adds incremental information about insider activity, but the transaction value is small and does not include any operational or financial catalyst.

02

Market read

Traders may note insider selling, but the disclosed sale size ($705.16) is unlikely to materially change valuation expectations.

03

What to watch

No 10b5-1 plan is stated, but the article provides no context on taxes, diversification, or pre-scheduled selling beyond the Form 4 fields.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-02, transaction dated 2026-06-30

Background

This is an SEC Form 4 insider transaction disclosure for Endava plc (DAVA) by director Druskin Ben.

Company-level read

Ticker impact

$DAVANeutralHigh confidence
Context

Endava plc Form 4 shows director Druskin Ben sold 244 shares at $2.8900 on 2026-06-30, totaling $705.16.

Expected impact

Limited, if any, impact on the stock price; any effect is likely short-lived.

Evidence & confidence

The filing is an insider sale with small dollar value ($705.16) and no 10b5-1 plan disclosed, but the transaction size is not material enough to drive repricing.

Market effects

No clear sector read-through from a small, single-insider sale.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management rather than a bearish signal, especially given the small size relative to typical insider holdings.

Key entities

  • Endava plc

    Company whose shares were sold by a director, disclosed via SEC Form 4.

  • Druskin Ben

    Director who sold 244 shares at $2.8900 on 2026-06-30.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DAVAMed

Here is Why Endava (DAVA) is One of the Underperforming Tech Stocks to Buy According to Analysts

Endava (NYSE:DAVA) reported FQ3 2026 revenue of £178.5 million, down 8.4% year over year, citing uneven demand and longer deal cycles. The company recorded a £364.6 million goodwill impairment and related tax charges, resulting in a diluted loss per share of £7.55. For FQ4, it expects revenue of £181.0–£185.0 million and adjusted diluted EPS of £0.09–£0.13.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).